Meeting of the Chronic Fatigue Syndrome Advisory Committee, 56042 [2017-25550]
Download as PDF
56042
Federal Register / Vol. 82, No. 226 / Monday, November 27, 2017 / Notices
HRSA specifically requests comments
on (1) the necessity and utility of the
proposed information collection for the
proper performance of the agency’s
functions, (2) the accuracy of the
estimated burden, (3) ways to enhance
the quality, utility, and clarity of the
information to be collected, and (4) the
use of automated collection techniques
or other forms of information
technology to minimize the information
collection burden.
Amy McNulty,
Acting Director, Division of the Executive
Secretariat.
[FR Doc. 2017–25507 Filed 11–24–17; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Chronic Fatigue
Syndrome Advisory Committee
Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
ACTION: Notice.
AGENCY:
As stipulated by the Federal
Advisory Committee Act, the U.S.
Department of Health and Human
Services (HHS) is hereby giving notice
that a meeting of the Chronic Fatigue
Syndrome Advisory Committee
(CFSAC) will take place and will be
open to the public.
DATES: The CFSAC in person meeting
will be held on Wednesday, December
13, 2017, from 9:00 a.m. until 3:30 p.m.
and Thursday, December 14, 2017, from
9:00 a.m. until 5:00 p.m. (EST).
ADDRESSES: U.S. Department of Health
and Human Services, Hubert H.
Humphrey Building, Room 800, 200
Independence Avenue SW.,
Washington, DC 20201.
FOR FURTHER INFORMATION CONTACT:
Commander Gustavo Ceinos, MPH,
Designated Federal Officer, Chronic
Fatigue Syndrome Advisory Committee,
Department of Health and Human
Services, 200 Independence Avenue
SW., Room 728F6, Washington, DC
20201. Please direct all inquiries to
cfsac@hhs.gov or 202–690–7650.
SUPPLEMENTARY INFORMATION: The
CFSAC is authorized under 42 U.S.C.
217a, Section 222 of the Public Health
Service Act, as amended. The purpose
of the CFSAC is to provide advice and
recommendations to the Secretary of
Health and Human Services, through
the Assistant Secretary for Health
(ASH), on issues related to myalgic
encephalomyelitis/chronic fatigue
asabaliauskas on DSKBBXCHB2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
16:59 Nov 24, 2017
Jkt 244001
syndrome (ME/CFS). The issues can
include factors affecting access and care
for persons with ME/CFS; the science
and definition of ME/CFS; and broader
public health, clinical, research, and
educational issues related to ME/CFS.
The agenda for this meeting, call-in
information and location will be posted
on the CFSAC Web site https://
www.hhs.gov/ash/advisory-committees/
cfsac/meetings/.
Request to speak to the committee:
Each day of the meeting an hour has
been scheduled for public comments via
telephone or in person. Individuals will
have three minutes to present their
comments. Priority will be given to
individuals who have not provided
public comment within the previous
twelve months. We are unable to place
international calls for public comments.
To request a time slot for public
comments, please send an email to
cfsac@hhs.gov by close of business on
Monday, November 27, 2017. The email
should contain the speaker’s name and
the phone number that will be used for
public comments.
An email from the CFSAC Support
Team will be sent back to you
confirming receipt of your request. If the
email confirmation is not received
within two working days, please call
202–690–7650.
Request to provide written comments:
Individuals who would like to provide
only written testimony to the Committee
members and do not wish to speak,
should indicate so in their email when
submitting their written testimony. It is
preferred, but not required, that the
submitted testimony be prepared in
digital format and typed using a 12pitch font. Written comments must not
exceed 5 single-space pages, and it is
preferred, but not required that the
document be prepared in the MS Word
format. Please note that PDF files,
handwritten notes, charts, and
photographs cannot be accepted.
Materials submitted should not include
sensitive personal information, such as
social security number, birthdates,
driver’s license number, passport
number, financial account number, or
credit or debit card number. If you wish
to remain anonymous please specify
this in your email, otherwise your name
will be included at the top of your
written comments.
The Committee welcomes input on
any topic related to ME/CFS.
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
Dated: November 17, 2017.
Gustavo Ceinos,
CDR, USPHS, Designated Federal Officer,
Chronic Fatigue Syndrome Advisory
Committee.
[FR Doc. 2017–25550 Filed 11–24–17; 8:45 am]
BILLING CODE 4150–42–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
Notice is hereby given that the Office
of Research Integrity (ORI) has taken
final action in the following case:
Mahandranauth Chetram, Ph.D.,
Georgetown University and Emory
School of Medicine: Based on the report
of an investigation conducted by
Georgetown University (GU),
Respondent’s admission at Emory
School of Medicine (ESOM), and
additional analysis conducted by ORI in
its oversight review, ORI found that Dr.
Mahandranauth Chetram, former
postdoctoral fellow, Department of
Oncology, GU, and former postdoctoral
fellow, Department of Pediatrics, ESOM,
engaged in research misconduct in
research supported by National Cancer
Institute (NCI), National Institutes of
Health (NIH), grants R01 CA113447, R01
CA092306, and T32 CA09686 while at
GU, and National Institute of Diabetes
and Digestive and Kidney Diseases
(NIDDK), NIH, grant R01 DK059380
while at ESOM.
ORI found that Respondent engaged
in research misconduct at GU by
falsifying Western blot images and
polymerase chain reaction (PCR) data
included in an unfunded grant
application, R01 CA193344–01A1, and
in a manuscript submitted to Cancer
Cell (‘‘The DNA Repair Protein, NTHL1
Functions as an Oncoprotein by
Activating the Canoncial Wnt Pathway.’’
Submitted to Cancer Cell; hereafter
referred to as the ‘‘Cancer Cell
manuscript’’). Subsequently, after
Respondent was aware of the research
misconduct findings from GU,
Respondent engaged in research
misconduct at ESOM and falsified RT–
PCR data on Excel spreadsheets in the
research record and in a figure
generated from the false data included
in a manuscript submitted to and
withdrawn from Scientific Reports
(‘‘Immipramine Blue Sensitively and
Selectively Targets FLT3–ITD Positive
Acute Myeloid Leukemia Cells.’’
Scientific Reports 7(1):4447, 2017 June
E:\FR\FM\27NON1.SGM
27NON1
Agencies
[Federal Register Volume 82, Number 226 (Monday, November 27, 2017)]
[Notices]
[Page 56042]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-25550]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Meeting of the Chronic Fatigue Syndrome Advisory Committee
AGENCY: Office of the Assistant Secretary for Health, Office of the
Secretary, Department of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: As stipulated by the Federal Advisory Committee Act, the U.S.
Department of Health and Human Services (HHS) is hereby giving notice
that a meeting of the Chronic Fatigue Syndrome Advisory Committee
(CFSAC) will take place and will be open to the public.
DATES: The CFSAC in person meeting will be held on Wednesday, December
13, 2017, from 9:00 a.m. until 3:30 p.m. and Thursday, December 14,
2017, from 9:00 a.m. until 5:00 p.m. (EST).
ADDRESSES: U.S. Department of Health and Human Services, Hubert H.
Humphrey Building, Room 800, 200 Independence Avenue SW., Washington,
DC 20201.
FOR FURTHER INFORMATION CONTACT: Commander Gustavo Ceinos, MPH,
Designated Federal Officer, Chronic Fatigue Syndrome Advisory
Committee, Department of Health and Human Services, 200 Independence
Avenue SW., Room 728F6, Washington, DC 20201. Please direct all
inquiries to cfsac@hhs.gov or 202-690-7650.
SUPPLEMENTARY INFORMATION: The CFSAC is authorized under 42 U.S.C.
217a, Section 222 of the Public Health Service Act, as amended. The
purpose of the CFSAC is to provide advice and recommendations to the
Secretary of Health and Human Services, through the Assistant Secretary
for Health (ASH), on issues related to myalgic encephalomyelitis/
chronic fatigue syndrome (ME/CFS). The issues can include factors
affecting access and care for persons with ME/CFS; the science and
definition of ME/CFS; and broader public health, clinical, research,
and educational issues related to ME/CFS.
The agenda for this meeting, call-in information and location will
be posted on the CFSAC Web site https://www.hhs.gov/ash/advisory-committees/cfsac/meetings/.
Request to speak to the committee: Each day of the meeting an hour
has been scheduled for public comments via telephone or in person.
Individuals will have three minutes to present their comments. Priority
will be given to individuals who have not provided public comment
within the previous twelve months. We are unable to place international
calls for public comments. To request a time slot for public comments,
please send an email to cfsac@hhs.gov by close of business on Monday,
November 27, 2017. The email should contain the speaker's name and the
phone number that will be used for public comments.
An email from the CFSAC Support Team will be sent back to you
confirming receipt of your request. If the email confirmation is not
received within two working days, please call 202-690-7650.
Request to provide written comments: Individuals who would like to
provide only written testimony to the Committee members and do not wish
to speak, should indicate so in their email when submitting their
written testimony. It is preferred, but not required, that the
submitted testimony be prepared in digital format and typed using a 12-
pitch font. Written comments must not exceed 5 single-space pages, and
it is preferred, but not required that the document be prepared in the
MS Word format. Please note that PDF files, handwritten notes, charts,
and photographs cannot be accepted. Materials submitted should not
include sensitive personal information, such as social security number,
birthdates, driver's license number, passport number, financial account
number, or credit or debit card number. If you wish to remain anonymous
please specify this in your email, otherwise your name will be included
at the top of your written comments.
The Committee welcomes input on any topic related to ME/CFS.
Dated: November 17, 2017.
Gustavo Ceinos,
CDR, USPHS, Designated Federal Officer, Chronic Fatigue Syndrome
Advisory Committee.
[FR Doc. 2017-25550 Filed 11-24-17; 8:45 am]
BILLING CODE 4150-42-P